Business StandardCenter·
Symbiotec Pharmalab makes tepid market debut, lists at par with IPO price
The listing of Symbiotec Pharmalab was well below GMP expectations, which had indicated a listing gain of around 18-19 per cent for IPO investors.
Read at Business Standard →




